Stock ZNTL ZENTALIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
10.62 USD -4.15% Intraday chart for Zentalis Pharmaceuticals, Inc. -10.61% -29.90%
May. 29 Zentalis Pharmaceuticals, Inc. Announces Appointment of Luke Walker, M.D., to Board of Directors and Audit Committee of the Board CI
May. 24 Zentalis Says Azenosertib Combo Shows 'Promise' in Relapsed Osteosarcoma Trial MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
AQ
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
AQ
Zentalis Pharmaceuticals, Inc. Announces Appointment of Luke Walker, M.D., to Board of Directors and Audit Committee of the Board
CI
Zentalis Says Azenosertib Combo Shows 'Promise' in Relapsed Osteosarcoma Trial
MT
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
AQ
Zentalis Pharmaceuticals, Inc. to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
CI
Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
AQ
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating
MT
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
AQ
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Zentalis Pharmaceuticals, Inc. Announces Executive Changes
CI
Zentalis Pharmaceuticals, Inc. Announces CFO Changes
CI
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS Inhibitors at AACR Annual Meeting 2024
AQ
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
AQ
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating That Wee1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity with Kras(G12c) Inhibitors At Aacr Annual Meeting 2024
CI
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Transcript : Zentalis Pharmaceuticals, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 03:20 PM
Zentalis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ZNTL Stock
  4. News Zentalis Pharmaceuticals, Inc.